Item 5. OTHER INFORMATION

Director Nominee Update

Dr. Ilham Kadri informed our Board of Directors (the "Board") on April 21, 2025 that, in light of the heightened commitments associated with her executive responsibilities amid the current macroeconomic climate, she has decided to withdraw her acceptance of her appointment to the Board. The Board initially appointed Dr. Kadri to serve as a director on the Board on March 28, 2025, effective with a term beginning May 1, 2025, as disclosed on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2025. Accordingly, Dr. Kadri will no longer join the Board on May 1, 2025 and will not stand for election as a director nominee at the Annual Meeting of Shareholders (the "Annual Meeting") and, upon conclusion of the Annual Meeting, the size of the Board will be nine members. Dr. Kadri's decision is not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies or practices.

Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements

During the three months ended March 31, 2025, certain of our officers or directors listed below adopted or terminated trading arrangements for the sale of shares of our Class A common stock in amounts and prices determined in accordance with a formula set forth in each such plan:


Name and Title	Action	Date	Plans	Number of Shares to be Sold		Expiration
Rule 10b5-1 (1)	Non-Rule 10b5-1 (2)
Rebecca Charlton, Senior Vice President - Controller & Chief Accounting Officer	Adoption	March 12, 2025	X	10,714	(3)	Earlier of when all shares under plan are sold and March 31, 2026
Maria Borras, Chief Growth & Experience Officer	Adoption	March 7, 2025	X	109,652		Earlier of when all shares under plan are sold and December 31, 2025
Lorenzo Simonelli, Chief Executive Officer	Adoption	March 5, 2025	X	173,350		Earlier of when all shares under plan are sold and December 31, 2025
Ganesh Ramaswamy, Executive Vice President of Industrial & Energy Technology	Adoption	March 5, 2025	X	50,000		Earlier of when all shares under plan are sold and May 7, 2026

(1)Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

(2)Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

(3)This figure is an estimation of after-tax sale amounts based on the Company's best estimates at this time

Baker Hughes Company 2025 First Quarter Form 10-Q | 34

Previous: Item 1A. RISK FACTORS · Next: Item 6. EXHIBITS